ClinicalTrials.gg
Not yet recruitingNCT07557927Updated Apr 30, 2026

A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus

A Phase 2 interventional study of Dihydroartemisinin tablets and Dihydroartemisinin tablets in Discoid Lupus Erythematosus, sponsored by Kunming Pharmaceuticals, Inc.. Not yet recruiting at 10 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Kunming Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid lupus erythematosus (DLE).

Read the detailed description

Participants are screened during the screening phase, and those meeting the inclusion criteria are enrolled in the study. Enrolled participants were randomised in a 2:2:1 ratio to Treatment Group 1 (dihydroartemisinin 40 mg, twice daily), Treatment Group 2 (dihydroartemisinin 60 mg, twice daily) or the control group (hydroxychloroquine 200 mg, once daily). Participants in all groups will receive treatment for 24 weeks, during which efficacy and safety will be monitored at regular intervals.

02

Conditions studied

  • Discoid Lupus Erythematosus
03

In context

Lupus Erythematosus, Discoid

42 studies on the registry are indexed under Lupus Erythematosus, Discoid; 7 are open to participants now.

This study's planned enrollment of 100 is above the median of 45 across 33 interventional studies indexed under Lupus Erythematosus, Discoid.

Browse Lupus Erythematosus, Discoid studies →

Lead sponsor

Kunming Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants are able to understand the purpose and risks of the study and voluntarily sign an form;
  2. Aged between 18 and 65 years (inclusive);
  3. Body weight ≥ 45 kg;
  4. Diagnosed with discoid lupus erythematosus (DLE) at the screening visit (refer to the '2021 Guidelines for the Diagnosis, Treatment and Long-term Management of Cutaneous Lupus Erythematosus'); new patients must undergo a skin and provide a pathology report, whilst existing patients must provide a biopsy pathology report dated within the last 5 years;
  5. At the time of screening, the Cutaneous Lupus Erythematosus Area and Severity Index (CLASI-A) must be ≥4.

Exclusion criteria

Exclusion Criteria:

  1. Patients with systemic lupus erythematosus (SLE) or those at high risk of developing SLE;
  2. Drug-induced lupus;
  3. Patients with a history of resistance to antimalarial treatment;
  4. At screening, (AST) or alanine transaminase (ALT) or gamma-glutamyltransferase (GGT) levels exceeding twice the (ULN); or alkaline phosphatase (ALP) or total levels exceeding 1.5 times the upper limit of normal (ULN); or serum creatinine (Cr) or urea (UREA) levels exceeding 1.5 times the upper limit of normal (ULN);
  5. Patients diagnosed with anaemia within 3 months prior to randomisation, or patients with levels below 110 g/L at screening;
  6. Patients who have used any antimalarial drug (hydroxychloroquine sulphate, chloroquine phosphate or chloroquine) within 4 weeks prior to randomisation;
  7. Patients who have used topical (e.g. mometasone furoate cream or others) or topical calcineurin inhibitors (e.g. tacrolimus ointment or others) within 2 weeks prior to randomisation;
  8. Patients treated with biologics (e.g. adalimumab, secukinumab or others) within 12 weeks prior to randomisation;
  9. Patients treated with immunomodulators (e.g. thalidomide, lenalidomide or others) within 4 weeks prior to randomisation;
  10. Patients who have received (e.g. measles vaccine, varicella vaccine or others) within 4 weeks prior to randomisation;
  11. Patients who have used traditional Chinese medicinal preparations with lupus-modulating effects within 4 weeks prior to randomisation, such as Tripterygium preparations (e.g. Tripterygium glycosides), Paeonia lactiflora total glycosides capsules, Zhengqing Fengtongning, or Euphorbia root tablets;
  12. History of malignant tumours within the 5 years prior to screening;
  13. History of acute myocardial infarction, unstable angina, or severe arrhythmias (multifocal frequent premature ventricular contractions, ventricular tachycardia, ventricular fibrillation) within the 6 months prior to screening, or (NYHA) Class III-IV;
  14. Conditions not effectively controlled at the time of screening or markedly unstable diseases (such as acute pneumonia, pulmonary arterial hypertension, diabetic ketoacidosis, acute pancreatitis, etc.), which, in the investigator's judgement, may confound the study results or expose the participant to undue risk;
  15. Patients with a history of major organ transplantation (e.g., heart, lung, kidney, liver) or haematopoietic stem cell and/or bone marrow transplantation within the 5 years prior to screening;
  16. A history of chronic, recurrent (three or more episodes of the same type of infection within 52 weeks) or recent severe infections (e.g. pneumonia, sepsis), including viral infections (particularly varicella and herpes zoster), or requiring anti-infective treatment during the screening period;
  17. Patients who have undergone any major surgery within 6 weeks prior to randomisation, such as abdominal, thoracic or joint replacement surgery, or who are scheduled to undergo major surgery during the study (including follow-up);
  18. Patients for whom the investigator, based on an ophthalmological examination prior to randomisation, considers the findings to be and unsuitable for participation in this clinical trial, or who have diseases associated with retinal pathology;
  19. Pregnant or breastfeeding women, or women of who do not agree to use effective during the clinical trial;
  20. Patients with known to artemisinin-based drugs, hydroxychloroquine or (lactose, microcrystalline cellulose, sodium carboxymethyl starch, sodium dodecyl sulphate, polyvinylpyrrolidone, magnesium stearate);
  21. Any other circumstances, as determined by the investigator, that may interfere with the assessment of efficacy.
  22. Individuals who abuse drugs or alcohol;
  23. Participants who have taken part in any clinical trial within the three months prior to screening (excluding those who underwent safety checks only and did not receive any substantive medication or therapeutic.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Treatment Group 1

    dihydroartemisinin 40 mg, twice daily

    Drug: Dihydroartemisinin tablets

  • Experimental
    Treatment Group 2

    dihydroartemisinin 60 mg, twice daily

    Drug: Dihydroartemisinin tablets

  • Active comparator
    control group

    hydroxychloroquine 200 mg, once daily

    Drug: Hydroxychloroquine tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in the Cutaneous Lupus Erythematosus Area and Severity Index (CLASI-A) score at week 24

    Time frame: Week 24

Secondary outcomes

  1. Percentage change from baseline in the Cutaneous Lupus Erythematosus Area and Severity Index (CLASI-A) score at weeks 2, 4, 8, 12, 16 and 20

    Time frame: weeks 2, 4, 8, 12, 16 and 20

  2. Change in CLASI-A score from baseline

    Time frame: weeks 2, 4, 8, 12, 16, 20 and 24

  3. Percentage of participants with a ≥50% reduction in CLASI-A score from baseline (CLASI-50)

    Time frame: weeks 2, 4, 8, 12, 16, 20 and 24

  4. Percentage of participants with a ≥20% reduction in CLASI-A score from baseline

    Time frame: weeks 2, 4, 8, 12, 16, 20 and 24

  5. Percentage of participants with a 4-point reduction in CLASI-A activity score from baseline

    Time frame: weeks 2, 4, 8, 12, 16, 20 and 24

  6. Percentage of participants achieving a complete response (CR) in CLASI-A (defined as a score of '0')

    Time frame: weeks 2, 4, 8, 12, 16, 20 and 24

  7. Proportion of participants with a post-treatment DLQI (Dermatology Life Quality Index) score reduced by 2 points or more compared to baseline

    Time frame: weeks 2, 4, 8, 12, 16, 20 and 24

  8. Mean change in post-treatment DLQI (Dermatology Life Quality Index) score compared to baseline

    Time frame: weeks 2, 4, 8, 12, 16, 20 and 24

  9. Mean change in post-treatment PGA (Physician Global Assessment) score compared to baseline

    Time frame: weeks 2, 4, 8, 12, 16, 20 and 24

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Sep 2028, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 30, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07557927
Lead sponsor
Kunming Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Duo Gao, bachelor
Contact
GAODUO5@kpc.com.cn
0871-68319868-3052
Yong Cui, MD
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artenimol

Start the discussion